Corsair Pharma, a clinical-stage biopharma company based in Newark, California, collaborated with our agency to develop a new website ahead of a major PH conference presentation. Its new digital presence features patient-focused storytelling, everyday lifestyle imagery, and streamlined biotech branding.
They hired our digital agency to design a brand-new website on a tight timeline, with a fully built, live site needed before their PH conference presentation. With a small internal team already stretched thin preparing for an FDA meeting and writing press releases, our teams needed to get right to work.
Their team had a specific challenge with how to present a technical pharmacological story. Corsair is developing TRX-248, an investigational once-daily treprostinil transdermal system for pulmonary arterial hypertension. Treprostinil has been a gold-standard PAH therapy for decades, but existing delivery methods, subcutaneous, intravenous, inhaled, or oral, all come with real drawbacks: infection risk, inconvenience, and inconsistent drug levels.
Beyond the timeline, Corsair needed their new website to make an inherently technical drug delivery mechanism feel approachable to patients, credible to treating physicians, and compelling to investors, all without overpromising on what the therapy could realistically deliver.
The Corsair Pharma team was involved at every stage, meeting with our team to review content, design, and imagery in real time. Rather than waiting on a slow website-building process, our designer began building homepage concepts directly from draft copy, allowing the site’s design and messaging to develop side by side.
Photography played a central role in the design. Our designer introduced a rotating collection of everyday lifestyle photography, rather than clinical or hospital imagery, centered on the line “Drug Delivery Designed for Daily Life.” Corsair‘s leadership was adamant that the site reflect patients being treated earlier in the disease, not the more severe imagery often associated with PAH.
Our teams worked together to responsibly gate more sensitive scientific material, like conference posters, behind a direct email request rather than posting it publicly, giving both patients and investors a clearer, more credible understanding of the therapy Corsair’s technology targets.
The result is a website that builds patient trust and investor confidence. It positions Corsair as a fast-moving clinical-stage biopharma company. The website was built, reviewed, and signed off in time to launch just ahead of Corsair’s PH conference appearance, giving the company a home for its data, its team, and its patients right when the audience that mattered most was paying attention.
The new Corsair Pharma website includes:
The redesigned website gives Corsair Pharma a platform to communicate its science, its patients, and its progress. It was launched in time to make a strong impression at the company’s most important conference appearance, and creates an engaging experience for every visitor to the Corsair Pharma website.
